| Company Name: |
Sigma-Aldrich |
| Tel: |
021-61415566 800-8193336 |
| Email: |
orderCN@merckgroup.com |
FK-506-13C-d2 manufacturers
- Tacrolimus-13C-d2
-
-
2026-07-30
- CAS:1356841-89-8
- Min. Order: 1kg
- Purity: 98
- Supply Ability: 1000kgs
- Tacrolimus-13C,D2
-
-
2023-05-27
- CAS:1356841-89-8
- Min. Order: 1mg
- Purity: 96%
- Supply Ability: 50 mg
|
| | FK-506-13C-d2 Basic information |
| Product Name: | FK-506-13C-d2 | | Synonyms: | (3S,4R,5S,8R,9E,12S,14S,15R,16S,18R,19R,26aS)-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-Hexadecahydro-5,19-dihydroxy-3-[(1E)-2-[(1R,3R,4R)-4-hydroxy-3-methoxycyclohexyl]-1-methylethenyl]-14,16-dimethoxy-4,10,12,18-tetramethyl-8-(2-propenyl-3-13C-d2)-15,19-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclotricosine-1,7,20,21(4H,23H)-tetrone;Tacrolimus-13C;Tacrolimus-13C,D2 solution;TACROLIMUS (13C, 99%;D2, 98%) 100 UG/ML IN ACETONITRILE;FK-506-13C,D2 (Major) (Tacrolimus)
(>;(3S,4R,5S,8R,9E,12S,14S,15R,16S,18R,19R,26aS)-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-Hexadecahydro-5,19-dihydroxy-3-[(1E)-2-[(1R,3R,4R)-4-hydroxy-3-methoxycyclohexyl]-1-methylethenyl]-14,16-dimethoxy-4,10,12,18-tetramethyl-8-(2-propenyl-3-13C-d2)-;FK-506-13C,D2 (Major) (Tacrolimus)(>85%) | | CAS: | 1356841-89-8 | | MF: | C44H67D2NO12 | | MW: | 807.02 | | EINECS: | | | Product Categories: | | | Mol File: | 1356841-89-8.mol |  |
| | FK-506-13C-d2 Chemical Properties |
| density | 1.194±0.10 g/cm3(Temp: 25 °C; Press: 760 Torr)(predicted) | | storage temp. | -70°C | | solubility | Chloroform: Slightly Soluble,Methanol: Slightly Soluble | | form | A solid | | color | White to yellow |
| RIDADR | UN 1648 3 / PGII | | WGK Germany | WGK 2 | | Storage Class | 3 - Flammable liquids | | Hazard Classifications | Acute Tox. 4 Dermal
Acute Tox. 4 Inhalation
Acute Tox. 4 Oral
Eye Irrit. 2
Flam. Liq. 2 |
| | FK-506-13C-d2 Usage And Synthesis |
| Description | FK-506-13C-d2 contains two deuterium atoms located on the carbon-13 bond. It is intended for use as an internal standard for the quantification of FK-506 by GC- or LC-MS. FK-506 is a potent, clinically-useful immunosuppressant in the same molecular class as cyclosporin A and rapamycin. Its mechanism of action involves the formation of a high affinity complex (Ki = 0.2 nM) with FK-506 Binding Protein 12 (FKBP12). This complex then inhibits the activity of the calcium/calmodulin-dependent protein phosphatase, calcineurin, leading to disruption of T cell activation. The physiological effects of FK-506 also include regulation of nitric oxide neurotoxicity, neurotransmitter release, and regulation of Ca2+ release via the ryanodine and inositol-(1,4,5)-trisphosphate (IP3) receptors. In the latter case, FKBP12 forms a tight complex with both ryanodine and IP3 receptors which can be disrupted by FK-506, thereby rendering the receptors “leaky” to Ca2+. | | Uses | A labelled immunosuppressant that blocks T cell proliferation in vitro by inhibiting the generation of several lymphokines, especially IL-2. Shown to inhibit the activity of FK-506 binding protein, thereby reversing its effects on sarcoplasmic reticulum Ca+2 release. A representative lot contained a distribution of 20% d-1, 40% d-2 and 20% d-3. | | General Description | This stable-labeled internal standard is suited for quantitation of tacrolimus by LC/MS or GC/MS for clinical toxicology, therapeutic drug monitoring, or isotope dilution methods. Tacrolimus, also known as FK-506 or fujimycin, is an immunosuppressive drug marketed as Prograf, Advagraf, and Protopic usually used to prevent rejection of organ transplants and treatment of eczema. Use of a stable-labeled analog of tacrolimus is the best choice to minimize variability or mitigate any potential interference in LC-MS/MS analysis. | | IC 50 | Macrolide | | References | [1] SCHREIBER S L. Chemistry and Biology of the Immunophilins and Their Immunosuppressive Ligands[J]. Science, 1991, 251 4991. DOI: 10.1126/science.1702904
[2] DUMONT F J. FK506, an immunosuppressant targeting calcineurin function.[J]. Current medicinal chemistry, 2000, 7 7: 731-748. DOI: 10.2174/0929867003374723
[3] S H SNYDER. Neural actions of immunophilin ligands.[J]. Trends in pharmacological sciences, 1998, 19 1: 21-26. DOI: 10.1016/s0165-6147(97)01146-2 |
| | FK-506-13C-d2 Preparation Products And Raw materials |
|